Loading
A mutation that keeps the cell's immortality enzyme switched on. In thyroid cancer, having it alongside BRAF marks the tumours most likely to spread and resist iodine.
TERT promoter mutations, chiefly C228T and C250T, keep the telomerase enzyme switched on and so remove one brake on replicative immortality. In thyroid cancer they occur in a minority of papillary cancers and in most anaplastic cancers, and their co-occurrence with BRAF V600E is synergistic for recurrence, distant metastasis and poor outcome, marking the tumours most likely to spread and resist radioiodine. The mutation is included in the ThyroSeq molecular classifier used on indeterminate thyroid nodules and is used for risk stratification. It is also a marker in melanoma, glioma and glioblastoma, and bladder and urothelial cancer. Readers meet it within the telomere maintenance pathway and the hallmark of enabling replicative immortality.
In plain words · BRAF is a signalling kinase mutated in half of melanomas; blocking it with two drugs at once became a template for targeted therapy.
Showing the target this term concerns: BRAF.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares BRAF, Thyroid cancer, Melanoma, Non-small-cell lung cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares BRAF, Melanoma, Non-small-cell lung cancer.
Shares Telomere maintenance & replicative immortality, Melanoma.
Shares Thyroid cancer, Bladder & urothelial cancer, Melanoma, Non-small-cell lung cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.
Shares Thyroid nodule FNA, Bethesda cytology & molecular classifiers, Thyroid cancer.